Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock
The diabetes-focused company reported adjusted loss of 78 cents per share, missing the consensus loss of 40 cents.
Tandem reported sales of $240.678 million, up 8% year over year, beating the consensus of $238.57 million.
Shipments in the United States grew to approximately 21,000 pumps. Shipments outside the United States were approximately 9,000 pumps.Outlook
Tandem Diabetes narrowed fiscal 2025 sales guidance from $997 million-$1.01 billion to $1 billion compared to the consensus of $1.004 billion.
'Our narrowed guidance reflects insights gained in the first half of the year, including our U.S. growth expectations as we progress our commercial transformation, increased benefit from accelerated pharmacy channel initiatives, and greater contributions from international sales,' said Leigh Vosseller, executive vice president and CFO.
Updated guidance includes sales in the United States of approximately $700 million.
Sales outside the United States of approximately $300 million reflect a $10 million headwind associated with the company's preparation for direct commercial operations in select countries.
Gross margin is estimated to be 53% to 54% of sales for the full year.
View more earnings on TNDM
Adjusted EBITDA margin is being recast from approximately 3% to approximately negative 5% of sales for the full year, which has been updated to include a negative 8 percentage point impact for an acquired in-process research and development charge that occurred in the first quarter of 2025.
Medical Device Correction
On Thursday, Tandem Diabetes also announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery.
The error, which appears as a Malfunction 16 alarm to the user, will stop insulin delivery and terminate communication between the insulin pump and the continuous glucose monitoring (CGM) device.
If not addressed, this could result in hyperglycemia due to discontinuation of insulin delivery, real-time CGM Estimated Glucose Values, and CGM trends.
There have been 700 confirmed adverse events, defined as a confirmed high blood sugar and/or an event requiring medical intervention, and 59 reported injuries. No deaths have been reported.
Analyst Reaction
Piper Sandler downgrades Tandem Diabetes Care from Overweight to Neutral and lowers the price forecast from $30 to $14.
Wells Fargo maintains Tandem with an Equal-Weight, lowering the price forecast from $20 to $13.
RBC Capital maintains Tandem Diabetes with an Outperform, lowering the price forecast from $45 to $25.
Price Action: TNDM stock is down 21.2% at $11.34 at the last check on Thursday.
Read Next:Photo via Shutterstock
Latest Ratings for TNDM
Date
Firm
Action
From
To
Feb 2022
Wells Fargo
Maintains
Overweight
Feb 2022
Citigroup
Maintains
Buy
Feb 2022
SVB Leerink
Maintains
Market Perform
View More Analyst Ratings for TNDM
View the Latest Analyst Ratings
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Udemy Launches AI-Powered Platform in Arabic, Fueling Skills Acceleration Across the Middle East
New expansion aims to empower over 300 million Arabic-speaking professionals with personalized, adaptive upskilling SAN FRANCISCO, August 14, 2025--(BUSINESS WIRE)--Udemy (Nasdaq: UDMY), a leading AI-powered skills acceleration platform, announced the recent launch of its platform in Arabic. This milestone reflects the global technology company's continued expansion across the Middle East, reinforcing Udemy's mission to empower learners and organizations worldwide with the skills they need to stay ahead in the age of AI. Spoken by more than 300 million people in various dialects, Arabic is one of the world's most widely used languages. The newly localized Udemy platform offers an enhanced user experience in Arabic, enabling organizations and professionals across the Middle East and North Africa region to upskill and reskill in high-growth, emerging roles. In the past year, over one million learners have enrolled in more than 7,000 Arabic-language courses from Udemy's Multi-Language Collection, covering a diverse range of topics from AI and cloud computing to communication and leadership. "At Udemy, we believe language should never be a barrier to professional growth," said Hugo Sarrazin, President and CEO of Udemy. "Localizing our platform in Arabic strengthens our ability to serve our growing customer base across the region with culturally relevant, high-quality reskilling experiences. With this launch, we're helping unlock new opportunities for workforce development, product innovation, and business growth throughout the Arabic-speaking world." "With Udemy's platform now available in Arabic, professionals in the region can seamlessly access high-quality, locally relevant learning experiences," said Dr. Ryan Ahmed, Udemy instructor, CEO of Stemplicity, and Assistant Professor at McMaster University. "This advancement not only removes language barriers but also empowers Arabic-speaking professionals and leaders to build critical skills with greater confidence, speed, and cultural resonance." Dr. Ahmed's course, Artificial Intelligence from Beginner to Professional, is available in Arabic to enterprise customers and learners on the Udemy platform. To access the Udemy platform in Arabic, visit About Udemy Udemy (Nasdaq: UDMY) is an AI-powered skills acceleration platform transforming how companies and individuals across the world build the capabilities needed to thrive in a rapidly evolving workplace. By combining on-demand, multi-language content with real-time innovation, Udemy delivers personalized experiences that empower organizations to scale workforce development and help individuals build the technical, business, and soft skills most relevant to their careers. Today, thousands of companies, including Ericsson, Samsung SDS America, On24, Tata Consultancy Services, The World Bank, and Volkswagen, rely on Udemy Business for its enterprise solutions to build agile, future-ready teams. Udemy is headquartered in San Francisco, with hubs across the United States, Australia, India, Ireland, Mexico, and Türkiye. View source version on Contacts Media Contact Risha TyagiSenior Global Corporate Communications Managerpress@
Yahoo
6 minutes ago
- Yahoo
Middle Eastern Penny Stocks: Gulf Pharmaceutical Industries P.S.C And Two More To Watch
The Middle Eastern stock markets have been experiencing mixed performances, with some indices buoyed by hopes of a U.S. Federal Reserve rate cut while others are weighed down by weaker corporate earnings. In this context, penny stocks—though an older term—remain relevant as they often represent smaller or less-established companies that can offer significant value when backed by strong financials. This article will highlight three such penny stocks in the Middle East, focusing on their potential for long-term growth and stability amidst current market conditions. Top 10 Penny Stocks In The Middle East Name Share Price Market Cap Financial Health Rating Big Tech 50 R&D-Limited Partnership (TASE:BIGT) ₪1.414 ₪15M ★★★★★★ Thob Al Aseel (SASE:4012) SAR3.71 SAR1.48B ★★★★★★ Mega Polietilen Köpük Sanayi ve Ticaret Anonim Sirketi (IBSE:MEGAP) TRY4.75 TRY1.31B ★★★★★☆ E7 Group PJSC (ADX:E7) AED1.47 AED3B ★★★★★★ Katmerciler Arac Üstü Ekipman Sanayi ve Ticaret (IBSE:KATMR) TRY2.97 TRY3.2B ★★★★★☆ Dubai National Insurance & Reinsurance (P.S.C.) (DFM:DNIR) AED3.45 AED392.7M ★★★★★★ Dubai Investments PJSC (DFM:DIC) AED2.89 AED12.25B ★★★★☆☆ Al Dhafra Insurance Company P.S.C (ADX:DHAFRA) AED4.86 AED486M ★★★★★★ Sharjah Cement and Industrial Development (PJSC) (ADX:SCIDC) AED0.828 AED488.43M ★★★★★★ Tgi Infrastructures (TASE:TGI) ₪2.937 ₪218.34M ★★★★★★ Click here to see the full list of 76 stocks from our Middle Eastern Penny Stocks screener. Here's a peek at a few of the choices from the screener. Gulf Pharmaceutical Industries P.S.C Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Gulf Pharmaceutical Industries P.S.C., also known as Julphar, manufactures and sells a range of pharmaceutical, cosmetic, and medical products in the UAE, GCC countries, and internationally with a market cap of AED1.68 billion. Operations: The company's revenue segments include AED732.9 million from Planet and AED864.9 million from Manufacturing. Market Cap: AED1.68B Gulf Pharmaceutical Industries P.S.C., known as Julphar, has shown a positive shift in its financial performance, reporting a net income of AED 157.9 million for the first half of 2025 compared to a net loss the previous year. The company's debt is well-managed with operating cash flow covering 31.1% and a reduced debt-to-equity ratio from 117% to 55.9% over five years, indicating improved financial health. Despite low return on equity at 2.4%, Julphar's profitability and stable weekly volatility are promising traits for investors interested in Middle Eastern penny stocks with potential growth prospects amidst operational challenges. Get an in-depth perspective on Gulf Pharmaceutical Industries P.S.C's performance by reading our balance sheet health report here. Examine Gulf Pharmaceutical Industries P.S.C's earnings growth report to understand how analysts expect it to perform. Sinpas Gayrimenkul Yatirim Ortakligi Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Sinpas Gayrimenkul Yatirim Ortakligi, originally established as Sinpas Insaat Anonim Sirketi in 2006 and transformed into a Real Estate Investment Trust (REIT) in 2007, operates in the real estate sector with a market capitalization of TRY17.76 billion. Operations: The company generates revenue primarily from its Residential Real Estate Developments segment, amounting to TRY12.64 billion. Market Cap: TRY17.76B Sinpas Gayrimenkul Yatirim Ortakligi has demonstrated robust financial health, with short-term assets of TRY14.8 billion comfortably covering both its short and long-term liabilities. The company has experienced significant earnings growth, notably an 86.4% increase over the past year, surpassing industry averages. However, a substantial one-off gain of TRY5.3 billion skews recent earnings quality. While its net debt to equity ratio is satisfactorily low at 14.2%, interest coverage remains weak at 2.1 times EBIT, suggesting potential pressure in meeting debt obligations despite stable weekly volatility and reduced debt levels over five years. Unlock comprehensive insights into our analysis of Sinpas Gayrimenkul Yatirim Ortakligi stock in this financial health report. Review our historical performance report to gain insights into Sinpas Gayrimenkul Yatirim Ortakligi's track record. Oil Refineries Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Oil Refineries Ltd. operates in the production and sale of fuel products, intermediate materials, and aromatic products both in Israel and internationally, with a market cap of ₪2.64 billion. Operations: Currently, there are no reported revenue segments for Oil Refineries Ltd. Market Cap: ₪2.64B Oil Refineries Ltd. faces challenges with a net loss of US$37 million in Q2 2025, contrasting with a profit last year. Despite this, its financial structure shows resilience; short-term assets of US$2 billion surpass both short and long-term liabilities. While the dividend yield is high at 10.22%, it isn't supported by earnings, raising sustainability concerns. Debt management has improved over five years, reducing from 127.7% to 75.3%. However, interest payments remain uncovered by EBIT and the company remains unprofitable despite shrinking losses annually by 25.8%. Management's experience offers some stability amid these hurdles. Dive into the specifics of Oil Refineries here with our thorough balance sheet health report. Explore historical data to track Oil Refineries' performance over time in our past results report. Turning Ideas Into Actions Click here to access our complete index of 76 Middle Eastern Penny Stocks. Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ADX:JULPHAR IBSE:SNGYO and TASE:ORL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
6 minutes ago
- Yahoo
One in four US adults with diabetes used a GLP-1 drug last year, survey finds
By Bhanvi Satija (Reuters) -More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the U.S. Centers for Disease Control and Prevention said on Thursday. The wildly popular and effective GLP-1 drugs Mounjaro from Eli Lilly and Ozempic from Novo Nordisk are approved in the United States for treating type 2 diabetes. They are sold as Zepbound and Wegovy, respectively, for weight loss and are being tested for other conditions. Use of the injectable drugs was highest among adults with diabetes aged 50–64 at 33.3%, reflecting the more significant disease burden in this group, the report said. A quarter or 25.3% of adults with diabetes aged 18 to 34 reported using a GLP-1 drug, while the adoption rate was 20.8% among those 65 and older. The data are from a nationally representative annual survey of U.S. adults aged 18 and older that was conducted in person and with follow-up by phone in 2024. In 2024, for the first time, participants in the annual survey who had diabetes were asked if they were using the Lilly or Novo blockbusters or other GLP-1 drugs to lower blood sugar or lose weight. The drugs mimic the activity of a hormone that regulates blood sugar levels, slows digestion and helps people feel full for longer. Drugmakers Lilly and Novo have faced criticism about the cost of the treatments, which carry a list price of about $1,000 for a month's supply. Roughly 31% of survey participants who reported using insulin also reported using GLP-1 drugs, as did about 28% of patients who were using oral drugs to control their blood sugar, according to the report, indicating that these treatments are being integrated into combination regimens. Hispanic adults with diabetes had the highest rate of GLP-1 use, at 31.3%, followed by Black non-Hispanic and White non-Hispanic adults, at 26.5% and 26.2%, respectively, the survey found. Only 12.1% of Asian non-Hispanic adults with diabetes used the drugs, which may reflect disparities in access or adoption of the therapies. Solve the daily Crossword
